Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03701061 · ClinicalTrials.gov registry record · Phase 4
Durability and Impact of the Seasonal Influenza Vaccine on H5 Induced B Cell Response
A Phase 4 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 4
- Development phase
- 12
- Enrollment target
NCT03701061 is a Phase 4 study that has completed, run by Emory University. The registered enrollment target is 12 participants.
The verdict
NCT03701061, a Phase 4 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 12 participants
- Enrollment target
Study Summary
The study is a prospective single site exploratory study to examine the impact of Food and Drug Administration (FDA) approved seasonal flu vaccine on the immune responses of H5N1 vaccine previously received with or without the AS03 adjuvant.
Interventions
- BIOLOGICAL Seasonal Influenza Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2018-10-11 |
| Est. Completion | 2020-01-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03701061
The ClinicalTrials.gov registry entry for NCT03701061 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Seasonal Influenza Vaccine is the first listed.
NCT03701061 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03701061 about?
NCT03701061 is a clinical study titled "Durability and Impact of the Seasonal Influenza Vaccine on H5 Induced B Cell Response". The study is a prospective single site exploratory study to examine the impact of Food and Drug Administration (FDA) approved seasonal flu vaccine on the immune responses of H5N1 vaccine previously received with or without the AS03 adjuvant.
What is the current status of trial NCT03701061?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 12 participants. The study started on 2018-10-11. Estimated completion is 2020-01-31.
What interventions are being tested in trial NCT03701061?
The interventions under investigation include: Seasonal Influenza Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT03701061?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.